Drugs / CROTEDUMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02284425 | Oct 2014 → Dec 2015 | type 2 diabetes mellitus | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01933763 | Aug 2013 → Jan 2015 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CROTEDUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707278 ↗ |
| Known as | REGN1193 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02284425 ↗ |
| Action | Inhibit | “Glucagon receptor inhibitor” CHEMBL3707278 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3707278 ↗ |
| Target | GCGR | “Glucagon receptor inhibitor” CHEMBL3707278 ↗ |